Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Alyssa Levin, formerly the CFO of Nkarta (NKTX), has joined Cyllene Therapeutics' Board of Directors as Chair of the Audit Committee. The release details Cyllene's strategic hires in regulatory affairs and CMC to support its lead candidate EG110A, a DNA medicine for neurogenic bladder currently in a Phase 1/2 study.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.